Physician profile
Tin S Wong
NPI 1588927552
$18,499.43
in general payments reported to CMS, 2019-2025
39 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what 95% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,883 · 2020: $2,047 · 2021: $3,850 · 2022: $2,223 · 2023: $2,300 · 2024: $2,035 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,493 · Travel and Lodging: $3.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,492.81 |
| Travel and Lodging | $3.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,550.88 | 2019-2025 | Creon, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,999.26 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $1,750.57 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $1,707.56 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $1,267.90 | 2021 | |
| Amarin Pharma, INC. | $1,014.68 | 2019-2023 | |
| Lilly USA, LLC | $864.22 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Phathom Pharmaceuticals, INC. | $857.45 | 2023-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $849.43 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $819.92 | 2020-2023 | Nexletol, Nexlizet |
| Gilead Sciences, INC. | $532.00 | 2019-2025 | Vemlidy |
| Pfizer INC. | $388.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $379.34 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Sanofi-Aventis U.S. LLC | $333.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $277.44 | 2019-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tin Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.